The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability of the following draft document available for public comment entitled "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List)." The document and instructions for submitting comments can be found at <a href="http://www.cdc.gov/niosh/docket/review/docket190/default.html">http://www.cdc.gov/niosh/docket/review/docket190/default.html</a>. Comments may be provided to the NIOSH Docket Number 190.

## NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List

Proposed Additions to Appendix A		
Established Name	AHFS Pharmacologic-Therapeutic Classification	
acitretin	88:04 Vitamin A	
ambrisentan	24:12.92 Vasodilating agents (endothelin receptor antagonists)	
bendamustine HCl	10:00 Antineoplastic agents	
cabergoline	28:36.20.04 Ergot-derived dopamine receptor agonists	
carbamazepine	28:12.92 Anticonvulsants, miscellaneous	
clonazepam	28:12.08 Benzodiazepines	
degarelix	10:00 Antineoplastic agents(GnRH receptor antagonist)	
dronedarone HCl	24:04.04 Antiarrythmic	
efavirenz	8:18.08.16 Non-nucleoside reverse transcriptase inhibitors	
everolimus	10:00 Antineoplastic agents	
ixabepilone	10:00 Antineoplastic agents	
mometasone furoate	68:04 Adrenals	
mycophenolic acid	91:44 Miscellaneous therapeutic agents (immunosuppressive agents)	
nilotinib	10:00 Antineoplastic agents	
oxcarbazepine	28:12.92 Anticonvulsants, miscellaneous	
paroxetine mesylate	28:16.04.20 Selective serotonin uptake inhibitors	
pazopanib HCl	10:00 Antineoplastic agents	
phenoxybenzamine HCl	12:16.04.04 Non-selective alpha-adrenergic blocking agents	
pitavastatin Ca	24:06.08 HMG-CoA reductase inhibitors	
plerixafor	20:16 hematopoietic agents	
pralatrexate	10:00 Antineoplastic agents	
romidepsin	10:00 Antineoplastic agents	
rufinamide	28:12.92 Anticonvulsants, miscellaneous	
simvastatin	24:06.08 HMG-CoA reductase inhibitors	
telavancin HCl	8:12.28.16 Glycopeptides	
temsirolimus	10:00 Antineoplastic agents	
tetracycline hydrochloride	8:12.24 Tetracyclines	
valproic acid/divalproex Na	28:12.92 Anticonvulsants, miscellaneous	
vigabatrin	28:12.92 Anticonvulsants, miscellaneous	
ziprasidone HCl	28:16.08.04 Atypical antipsychotics	
zoledronic acid	92:24 Bone resorption inhibitors	
	Proposed Deletions to Appendix A	
Drugs reclassified as not mee	eting criteria for a hazardous drug	
alemtuzumab	10:00 Antineoplastic agents	
interferon alfa 2a	10:00 Antineoplastic agents	
interferon alfa 2b	10:00 Antineoplastic agents	

interferon alfa n3	10:00 Antineoplastic agents
NIOSH proposes to remove	these radio-pharmaceuticals from the current list because they are atory Commission, which directs how they are handled
ibritumomab tiuxetan	10:00 Antineoplastic agents
tositumomab	10:00 Antineoplastic agents
	these drugs because they are currently not available in the United
States	
dienestrol	68:16.04 Estrogens
interferon alfa n1	10:00 Antineoplastic agents
perphosphamide	Not in AHFS (antineoplastic agent)
piritrexim isethionate	Not in AHFS (antineoplastic agent)
plicamycin	Not in AHFS (antineoplastic agent)
prednumustine	Not in AHFS (antineoplastic agent)
raltitrexed	Not in AHFS (antineoplastic agent)
trimetrexate glucuronate	8:30.92 Miscellaneous antiprotozoals
vindesine	Not in AHFS (antineoplastic agent)